Moolec Science (MLEC) Return on Capital Employed (2023 - 2024)
Moolec Science's (MLEC) quarterly Return on Capital Employed came in at 75.2% in Q4 2024, down 62334.0% year-on-year from N/an in Q1 2024, and up 1770.52% quarter-over-quarter from 4.02% in Q3 2024.
Moolec Science (MLEC) Return on Capital Employed (2023 - 2024) Analysis & Trends
Moolec Science has disclosed Return on Capital Employed across 2 years of filings, most recently posting 75.2% for Q4 2024.
- Return on Capital Employed for Q4 2024 came in at 75.2%, down 62334.0% year-over-year; the trailing twelve-month figure through Dec 2024 was 75.2% (down 62334.0% YoY), and the FY2024 annual result was 32.39%, down 338032.0% from the prior year.
- Return on Capital Employed came in at 75.2% for Q4 2024 at Moolec Science, up from 4.02% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 2819.83% in Q2 2023 to a low of 4.02% in Q3 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 723,416.35 Bn | 723,416.32 Bn | - | - |
| 2 | Belite Bio | 57,340.00 Bn | 57,340.00 Bn | - | - |
| 3 | Quantum Biopharma | 19,125.08 Bn | 19,125.08 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,262.00 Bn | 3,261.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,789.67 Bn | 1,789.67 Bn | - | -107.40% |
| 6 | Evaxion A | 1,480.39 Bn | 1,480.37 Bn | - | - |
| 7 | Psyence Biomedical | 241.78 Bn | 241.78 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.54 Bn | 106.29 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 94.26 Bn | 94.26 Bn | - | -50.43% |
| 10 | Moolec Science | 6.98 Bn | 6.98 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 75.20% |
| Sep 30, 2024 | 4.02% |
| Jun 30, 2024 | 31.88% |
| Mar 31, 2024 | 597.61% |
| Dec 31, 2023 | 698.54% |
| Sep 30, 2023 | 896.95% |
| Jun 30, 2023 | 2,819.83% |
| Mar 31, 2023 | 258.83% |